---
title: "Absci 盘中急涨 现涨近 42% 试验数据积极"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290725296.md"
description: "Absci(ABSI.US) 盘中急涨，现报 10.515 美元。ABS-201 脱发药试验数据积极，公司完成 1 亿美元融资。"
datetime: "2026-06-24T17:51:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290725296.md)
  - [en](https://longbridge.com/en/news/290725296.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290725296.md)
generator: "portal-rs"
---

# Absci 盘中急涨 现涨近 42% 试验数据积极

Absci(ABSI.US) 盘中急涨，现涨近**42%**，现报**10.515**美元。

消息面上，公司 ABS-201 抗体药物的中期 1 期临床试验数据积极，该药物针对雄激素性脱发适应症，显示出良好的安全性特征，估计半衰期至少**65**天，支持每六个月进行两到三次注射的给药方案。

此外，公司近日完成**1**亿美元普通股承销发行，发行价为每股**7.41**美元，战略投资者包括礼来公司（Eli Lilly & Company）。募资将用于推进 ABS-201 项目研发及营运资金。

### Related Stocks

- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)

## Related News & Research

- [Absci (ABSI) Could Be 32% Undervalued Following ABS 201 Data And Earnings](https://longbridge.com/en/news/295686913.md)
- [AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained](https://longbridge.com/en/news/295652271.md)
- [Absci director Mary T Szela acquires 12,900 common shares for $148,866](https://longbridge.com/en/news/291839359.md)
- [Absci Q2 revenue falls and misses analyst expectations](https://longbridge.com/en/news/295574634.md)
- [Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/290920860.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**